Nutex Health, INC

Nutex Health Inc. has amended its Payment Dispute Resolution Services Agreement with HaloMD, L.L.C., changing the fee structure and extending the agreement term.

Nutex Health Inc. announced the results of its annual meeting of stockholders held on April 23, 2026, where all seven director nominees were elected and executive compensation was approved.

Nutex Health Inc. announced robust full-year 2025 financial results with significant revenue and profit growth, alongside a new $25 million stock repurchase program, despite a challenging fourth quarter.

Nutex Health Inc. filed an auditor's consent for the incorporation by reference of financial reports into several Form S-8 registration statements.

Nutex Health Inc. announced significantly improved financial and operating results for the third quarter and first nine months of 2025, marked by substantial revenue and profit growth.

Nutex Health Inc. announced significant revenue and Adjusted EBITDA growth for the first half of 2025, alongside a new $25 million stock repurchase program.

Nutex Health Inc. reported a significant turnaround in Q3 2025, achieving substantial net income and revenue growth driven by its hospital division and successful independent dispute resolution outcomes.

Nutex Health posted a 221% jump in total revenue to $244M and strong operating income in Q2 2025, but recorded a $17.7M loss attributable to common shareholders amid large stock-based charges and high noncontrolling interests.

Nutex Health amended Q1 2025 results to reclassify stock-based obligations as liabilities, lifting EPS and net income while reaffirming a material weakness in internal controls.

Nutex Health Inc. announces a significant increase in net income and revenue for the first quarter of 2025, driven by higher patient visits and successful arbitration efforts.

Nutex Health Inc. saw a significant increase in revenue and adjusted EBITDA in the third quarter of 2024, driven by higher patient visits and improved reimbursement rates, though the company still reported a net loss.

Nutex Health saw a significant improvement in its second quarter results, driven by increased patient visits and higher revenue per visit, despite ongoing challenges with the No Surprises Act.

Nutex Health Inc. reported significant revenue and net income growth in 2025, driven by its hospital division and successful navigation of the No Surprises Act's arbitration process, despite facing ongoing litigation and regulatory uncertainties.

Nutex Health Inc. reported a significant financial turnaround in 2024 with a net income of $52.1 million, driven by a 93.8% revenue increase to $479.9 million, despite restating prior financials and identifying additional material weaknesses in internal controls.

Nutex Health files an amendment to its annual report to include previously omitted information regarding directors, executive officers, corporate governance, executive compensation, security ownership, related person transactions, and principal accountant fees.

Nutex Health's 2024 10-K filing highlights strategic growth, regulatory navigation, and financial performance amid evolving healthcare dynamics.

Nutex Health has filed an amendment to its annual report to include previously omitted information regarding directors, executive compensation, and related matters.

Nutex Health Inc. has issued a convertible promissory note and warrants to an unnamed holder, outlining terms for repayment, interest, and potential conversion to common stock.

Frank E Jaumot, a Director of Nutex Health, Inc., reported a transaction in 603 shares of common stock on July 31, 2026.

Cheryl Yvonne Grenas, a Director of Nutex Health, Inc., reported a transaction in 603 shares of common stock on July 31, 2026.

Scott J Saunders, a Director of Nutex Health, Inc., reported a transaction in 603 shares of common stock on July 31, 2026.

Michael Lee Reed, a Director of Nutex Health, Inc., reported a transaction in 603 shares of common stock on July 31, 2026.

Nutex Health Inc. Director Kelvin Spears reported the acquisition of 2,519 shares of common stock on June 4, 2026, as part of a private transaction related to prior merger obligations.

Nutex Health CEO Thomas T. Vo acquired 75,747 shares of common stock through an indirect holding entity.

Nutex Health Inc. announced its 2026 Annual Meeting of Stockholders to be held virtually on April 23, 2026, focusing on director re-elections, executive compensation, and auditor ratification.

Nutex Health Inc. announced the filing of a supplement to its definitive proxy statement, urging shareholders to review it in preparation for the upcoming Annual Meeting on July 14, 2025.

Nutex Health Inc. has issued a supplement to its proxy statement, providing additional disclosures on the potential dilutive impact of its proposed equity incentive plan amendment and detailing significant stock-based compensation related to prior hospital mergers.

Nutex Health Inc. has issued a supplement to its proxy statement, clarifying the voting requirements for its 2023 Equity Incentive Plan amendment and confirming agenda items for its July 14, 2025 Annual Meeting, including director re-elections and a new board nominee.

Nutex Health Inc. has announced the internet availability of its definitive proxy materials for its 2025 annual meeting, which will be held virtually on July 14, 2025.

Nutex Health Inc. has announced its 2025 Annual Meeting of Stockholders for July 14, 2025, where shareholders will vote on director elections, executive compensation, and a significant increase in the company's equity incentive plan shares.

Pertento Partners LLP, Pertento Advisors LLC, Pertento Master Fund Limited, and Eduardo Marques have filed an amendment to Schedule 13G, reporting beneficial ownership of Nutex Health, Inc. common stock.

Pertento Partners LLP and Eduardo Marques have disclosed a 4.6% beneficial ownership stake in Nutex Health, Inc., holding 324,422 shares of common stock.

Pertento Partners LLP and Eduardo Marques have reported a 5.1% beneficial ownership stake in Nutex Health, Inc., totaling 286,799 shares of common stock.

Topline Capital Management and affiliates disclosed a 9.9% passive beneficial ownership in Nutex Health, Inc. common stock.

Topline Capital Management, LLC, along with Collin McBirney and Topline Capital Partners, LP, has reported a 5.1% beneficial ownership stake in Nutex Health, Inc.'s common stock.

Highbridge Capital Management, LLC has filed an amended Schedule 13G, indicating it no longer holds any beneficial ownership in Nutex Health, Inc. as of December 31, 2024.